- Revenues of EUR 2.5 million generated in the first half of 2024 (H1 2023: EUR 5.2 million); cash and cash equivalents as of 30.06.2024 at EUR 0.9 million (31.12.2023: EUR 2.6 million)
- Court restructuring proceedings without self-administration opened on August 14, 2024; Marinomed shares now listed in the standard market continuous segment of the Vienna Stock Exchange
- New partnerships for Carragelose and Solv4U and progress with new Carragelose products
The full press release is available here: